For Nexavar In Lung Cancer, Focus Moves From First To Second Line
This article was originally published in The Pink Sheet Daily
Executive Summary
Nexavar failed to meet the primary endpoint of a second Phase III trial in first-line lung cancer, but Bayer/Onyx remain optimistic about prospects for the drug in the disease based on biomarkers.